Abstract 182P
Background
Gastric adenocarcinoma (GA) with peritoneal carcinomatosis is associated with poor prognosis with median overall survival surfacing under the one-year mark. The treatment of gastric cancer remains controversial. Using hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery may help reduce mortality rates. This study attempted to investigate treatment modalities available for metastatic gastric adenocarcinoma.
Methods
We extracted all adult patients with intestinal-type gastric adenocarcinoma with 7th edition AJCC M1 stage (2010-2015) using the Surveillance Epidemiology and End Results (SEER) database. Patients with extra-peritoneal metastasis were excluded. We stratified patients into four different groups: surgery, chemotherapy, surgery and chemotherapy, and no surgery/no chemotherapy. Kaplan-Meier and Cox proportional hazard regression models were utilized to access overall survival (OS) and cancer-specific survival (CSS).
Results
A total of 243 patients were identified. The median (OS) of the entire cohort was 11 months. Patients who received both chemotherapy and surgery, chemotherapy alone, and surgery alone had higher median (OS) compared to no treatment [19, 13, and 6 months, respectively, vs 3 months, p<0.001], as well as a higher (CSS) (p<0.0001). Patients who received no therapy had a statistically significant risk of overall mortality compared to the chemotherapy and surgery group [HR= 9.28 (5.40 -15.94). p<0.001], and compared to other treatment groups (p<0.001). N3B Stage was a significant risk factor for (OS) and (CSS) [HR= 2.69 (1.23 -5.78), p<0.013]. Table: 182P
Median overall survival
N | Events | Median survival | 95% CI | |
Overall Survival (OS) | ||||
No treatment administered | 56 | 54 | 3 | (2- 5) |
Chemotherapy alone | 91 | 86 | 13 | (11- 17) |
Surgery alone | 32 | 29 | 6 | (3- 16) |
Both chemotherapy and surgery | 64 | 55 | 19 | (16- 29) |
Cancer-Specific Survival (CSS) | ||||
No treatment administered | 56 | 53 | 3 | (2- 5) |
Chemotherapy alone | 87 | 75 | 13 | (11-18) |
Surgery alone | 30 | 21 | 15 | (4-43) |
Both chemotherapy and surgery | 62 | 49 | 19 | (16-31) |
Conclusions
The combined usage of surgery and chemotherapy significantly improved the median overall and cancer-specific survival for (GA) patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract